Spotlight on Nephrology
An Integrated Approach to Chronic Active AMR in Renal Transplantation: Tying Together Pathogenesis, Diagnosis, and Emerging Treatment — Deciphering the Root Cause of Chronic Active Antibody-Mediated Rejection in Renal Transplant
StartActivity Details
Expires: June 6, 2023
Provided By
RMEI Medical Education, LLC
Target Audience
This activity is intended for transplant, nephrology, general surgery, and internal medicine clinicians involved in care of patients with antibody-mediated rejection (AMR).
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Examine the pathogenic mechanisms responsible for the deleterious clinical manifestations of chronic active antibody-mediated rejection (AMR) in kidney transplant recipients
- Employ established criteria to diagnose kidney transplant recipients with chronic active AMR
Activity Description
This learner-friendly, 30-minute infographic activity is augmented by expert and patient videos with an interactive approach to examining the pathogenic mechanisms responsible for the deleterious clinical manifestations of chronic active antibody mediated-rejection (AMR) in kidney transplant recipients. Important highlights include risk factors and diagnostic criteria for chronic active AMR.
Faculty
Director, Nephrology & Transplant Immunology
Medical Director, Kidney Transplant Program
Cedars-Sinai Medical Center
Los Angeles, CA
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Stanley C. Jordan, MD, FASN, FAST, has relevant financial relationships with Argenx, CareDx, CSL Behring, Hansa, Regeneron, Vera (Consultant); CSL Behring, Hansa, One Legacy (Grant/Research Support).
Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial
relationship(s) with ineligible companies to disclose.
Joint Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC) to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only
the credit commensurate with the extent of their participation in the
activity.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
There is no fee to participate.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an independent educational grant from CSL Behring LLC.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Activity Details
Expires: June 6, 2023
Provided By
RMEI Medical Education, LLC
Target Audience
This activity is intended for transplant, nephrology, general surgery, and internal medicine clinicians involved in care of patients with antibody-mediated rejection (AMR).
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Examine the pathogenic mechanisms responsible for the deleterious clinical manifestations of chronic active antibody-mediated rejection (AMR) in kidney transplant recipients
- Employ established criteria to diagnose kidney transplant recipients with chronic active AMR
Activity Description
This learner-friendly, 30-minute infographic activity is augmented by expert and patient videos with an interactive approach to examining the pathogenic mechanisms responsible for the deleterious clinical manifestations of chronic active antibody mediated-rejection (AMR) in kidney transplant recipients. Important highlights include risk factors and diagnostic criteria for chronic active AMR.
Faculty
Director, Nephrology & Transplant Immunology
Medical Director, Kidney Transplant Program
Cedars-Sinai Medical Center
Los Angeles, CA
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Stanley C. Jordan, MD, FASN, FAST, has relevant financial relationships with Argenx, CareDx, CSL Behring, Hansa, Regeneron, Vera (Consultant); CSL Behring, Hansa, One Legacy (Grant/Research Support).
Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial
relationship(s) with ineligible companies to disclose.
Joint Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC) to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only
the credit commensurate with the extent of their participation in the
activity.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
There is no fee to participate.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an independent educational grant from CSL Behring LLC.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Nephrology Presentations
Pathways to Improved Care in FSGS and IgAN – Kidney Week Conference Coverage
StartActivity Details
Expires: November 11, 2023
Accredited By
Target Audience
This activity is intended for nephrologists, primary care, internal medicine, and other clinicians interested in treating patients with Focal Segmental Glomerulosclerosis and/or IgA Nephropathy.
Learning Objectives
Upon completion of this activity, participants will be able to:
- Discuss challenges in the care and pharmacologic management of patients with FSGS or IgAN
- Outline emerging therapies and pathways for FSGS and IgAN
- Interpret clinical trial data and endpoints from clinical trials with emerging therapies
Activity Description
In this brief video, Dr. Edgar Lerma explores data on focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) coming out of ASN 2022. Dr. Lerma discusses current challenges in diagnosing and managing these kidney diseases, and how emerging data and therapies may impact current clinical practice.
Statement of Educational Need
The treatment of focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) is challenging due to disease heterogeneity and a lack of therapeutic approaches. A number of therapies, including some with novel mechanisms of action, are under investigation for treating these progressive kidney diseases. Therefore, clinicians need up-to-date understanding of these therapies and available efficacy and safety data to incorporate them into treatment paradigms once they are available.
Agenda
Dr. Lerma will discuss current barriers, emerging evidence, and strategies to incorporate advances.
Faculty
Clinical Professor of Medicine
Section of Nephrology
University of Illinois at Chicago
Chicago, IL
Conflict of Interest Policy/Disclosure Statement
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.
The following financial relationships have been provided:
Edgar V. Lerma, MD, FASN, FNKF, FPSH (Hon) (Faculty)
Advisor or Review Panel Member: Akebia, AstraZeneca, Bayer, GlaxoSmithKline,
Otsuka, Travere, Vifor
Honorarium: Akebia, AstraZeneca, Bayer, GlaxoSmithKline, Otsuka, Travere,
Vifor
Speaker Bureau: Bayer, GlaxoSmithKline
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Agents (Atrasentan, sparsentan, and DMX-200) under investigation for FSGS and IgAN.
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
Accreditation Statement
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
This activity will take approximately 15 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 50% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
Statement of Commercial Support
Supported by an educational grant from Travere Therapeutics, Inc.
Disclaimer Statement/Disclosure of Unlabeled Use
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
Contact Information for Questions
For questions, contact Laurie Novoryta at Lnovoryta@achlcme.org.
Activity Details
Expires: November 11, 2023
Accredited By
Target Audience
This activity is intended for nephrologists, primary care, internal medicine, and other clinicians interested in treating patients with Focal Segmental Glomerulosclerosis and/or IgA Nephropathy.
Learning Objectives
Upon completion of this activity, participants will be able to:
- Discuss challenges in the care and pharmacologic management of patients with FSGS or IgAN
- Outline emerging therapies and pathways for FSGS and IgAN
- Interpret clinical trial data and endpoints from clinical trials with emerging therapies
Activity Description
In this brief video, Dr. Edgar Lerma explores data on focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) coming out of ASN 2022. Dr. Lerma discusses current challenges in diagnosing and managing these kidney diseases, and how emerging data and therapies may impact current clinical practice.
Statement of Educational Need
The treatment of focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) is challenging due to disease heterogeneity and a lack of therapeutic approaches. A number of therapies, including some with novel mechanisms of action, are under investigation for treating these progressive kidney diseases. Therefore, clinicians need up-to-date understanding of these therapies and available efficacy and safety data to incorporate them into treatment paradigms once they are available.
Agenda
Dr. Lerma will discuss current barriers, emerging evidence, and strategies to incorporate advances.
Faculty
Clinical Professor of Medicine
Section of Nephrology
University of Illinois at Chicago
Chicago, IL
Conflict of Interest Policy/Disclosure Statement
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.
The following financial relationships have been provided:
Edgar V. Lerma, MD, FASN, FNKF, FPSH (Hon) (Faculty)
Advisor or Review Panel Member: Akebia, AstraZeneca, Bayer, GlaxoSmithKline,
Otsuka, Travere, Vifor
Honorarium: Akebia, AstraZeneca, Bayer, GlaxoSmithKline, Otsuka, Travere,
Vifor
Speaker Bureau: Bayer, GlaxoSmithKline
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Agents (Atrasentan, sparsentan, and DMX-200) under investigation for FSGS and IgAN.
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
Accreditation Statement
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
This activity will take approximately 15 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 50% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
Statement of Commercial Support
Supported by an educational grant from Travere Therapeutics, Inc.
Disclaimer Statement/Disclosure of Unlabeled Use
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
Contact Information for Questions
For questions, contact Laurie Novoryta at Lnovoryta@achlcme.org.
An Integrated Approach to Chronic Active AMR in Renal Transplantation: Tying Together Pathogenesis, Diagnosis, and Emerging Treatment — Deciphering the Root Cause of Chronic Active Antibody-Mediated Rejection in Renal Transplant
StartActivity Details
Expires: June 6, 2023
Provided By
RMEI Medical Education, LLC
Target Audience
This activity is intended for transplant, nephrology, general surgery, and internal medicine clinicians involved in care of patients with antibody-mediated rejection (AMR).
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Examine the pathogenic mechanisms responsible for the deleterious clinical manifestations of chronic active antibody-mediated rejection (AMR) in kidney transplant recipients
- Employ established criteria to diagnose kidney transplant recipients with chronic active AMR
Activity Description
This learner-friendly, 30-minute infographic activity is augmented by expert and patient videos with an interactive approach to examining the pathogenic mechanisms responsible for the deleterious clinical manifestations of chronic active antibody mediated-rejection (AMR) in kidney transplant recipients. Important highlights include risk factors and diagnostic criteria for chronic active AMR.
Faculty
Director, Nephrology & Transplant Immunology
Medical Director, Kidney Transplant Program
Cedars-Sinai Medical Center
Los Angeles, CA
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Stanley C. Jordan, MD, FASN, FAST, has relevant financial relationships with Argenx, CareDx, CSL Behring, Hansa, Regeneron, Vera (Consultant); CSL Behring, Hansa, One Legacy (Grant/Research Support).
Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial
relationship(s) with ineligible companies to disclose.
Joint Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC) to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only
the credit commensurate with the extent of their participation in the
activity.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
There is no fee to participate.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an independent educational grant from CSL Behring LLC.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Activity Details
Expires: June 6, 2023
Provided By
RMEI Medical Education, LLC
Target Audience
This activity is intended for transplant, nephrology, general surgery, and internal medicine clinicians involved in care of patients with antibody-mediated rejection (AMR).
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Examine the pathogenic mechanisms responsible for the deleterious clinical manifestations of chronic active antibody-mediated rejection (AMR) in kidney transplant recipients
- Employ established criteria to diagnose kidney transplant recipients with chronic active AMR
Activity Description
This learner-friendly, 30-minute infographic activity is augmented by expert and patient videos with an interactive approach to examining the pathogenic mechanisms responsible for the deleterious clinical manifestations of chronic active antibody mediated-rejection (AMR) in kidney transplant recipients. Important highlights include risk factors and diagnostic criteria for chronic active AMR.
Faculty
Director, Nephrology & Transplant Immunology
Medical Director, Kidney Transplant Program
Cedars-Sinai Medical Center
Los Angeles, CA
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Stanley C. Jordan, MD, FASN, FAST, has relevant financial relationships with Argenx, CareDx, CSL Behring, Hansa, Regeneron, Vera (Consultant); CSL Behring, Hansa, One Legacy (Grant/Research Support).
Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial
relationship(s) with ineligible companies to disclose.
Joint Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC) to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only
the credit commensurate with the extent of their participation in the
activity.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
There is no fee to participate.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an independent educational grant from CSL Behring LLC.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.